UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 684

Sortiert nach

Active-comparator design and new-user design in observational studies

Nature reviews. Rheumatology, 2015-07, Vol.11 (7), p.437

2015

Link zum Volltext

Verfügbarkeit prüfen

Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study

Annals of the rheumatic diseases, 2022-06, Vol.81 (6), p.798

2022

Link zum Volltext

Verfügbarkeit prüfen

A MaxEnt learner for super-additive counting cumulativity

Glossa (London), 2022-07, Vol.7 (1)

Kim, Seoyoung

2022

Link zum Volltext

Verfügbarkeit prüfen

Bisphosphonates and risk of cardiovascular events: a meta-analysis

PloS one, 2015-04, Vol.10 (4), p.e0122646-e0122646

2015

Link zum Volltext

Verfügbarkeit prüfen

Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study

Annals of internal medicine, 2020-02, Vol.172 (3), p.186

2020

Link zum Volltext

Verfügbarkeit prüfen

Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease

Clinical gastroenterology and hepatology, 2022-02, Vol.20 (2), p.314-324.e16

2022

Link zum Volltext

Verfügbarkeit prüfen

Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study

Arthritis & rheumatology (Hoboken, N.J.), 2019-06, Vol.71 (6), p.892-900

2019

Link zum Volltext

Verfügbarkeit prüfen

Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study

Annals of internal medicine, 2019-02, Vol.170 (3), p.155

2019

Link zum Volltext

Verfügbarkeit prüfen

Shift From Adalimumab Originator to Biosimilars in Denmark

JAMA internal medicine, 2020-06, Vol.180 (6), p.902

2020

Link zum Volltext

Verfügbarkeit prüfen

Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta‐analysis

Journal of bone and mineral research, 2013-08, Vol.28 (8), p.1729-1737

2013

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study

Arthritis & rheumatology (Hoboken, N.J.), 2017-06, Vol.69 (6), p.1154-1164

2017

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout

European heart journal, 2021-11, Vol.42 (44), p.4578-4588

2021

Link zum Volltext

Verfügbarkeit prüfen

An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout

PloS one, 2018-02, Vol.13 (2), p.e0193622-e0193622

2018

Link zum Volltext

Verfügbarkeit prüfen

When Randomized Clinical Trials and Real‐World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety

Arthritis & rheumatology (Hoboken, N.J.), 2020-01, Vol.72 (1), p.4-6

2020

Link zum Volltext

Verfügbarkeit prüfen

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis

Cardiovascular diabetology, 2022-03, Vol.21 (1), p.47-47, Article 47

2022

Link zum Volltext

Verfügbarkeit prüfen

Calibrating Real‐World Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Crohn’s Disease

Clinical pharmacology and therapeutics, 2022-01, Vol.111 (1), p.179-186

2022

Link zum Volltext

Verfügbarkeit prüfen

Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study

Annals of the rheumatic diseases, 2019-04, Vol.78 (4), p.456

2019

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

BMJ (Online), 2018-02, Vol.360, p.k119

2018

Link zum Volltext

Verfügbarkeit prüfen

Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis

Arthritis care & research (2010), 2013-10, Vol.65 (10), p.1600-1607

2013

Link zum Volltext

Verfügbarkeit prüfen

Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims

Annals of the rheumatic diseases, 2016-09, Vol.75 (9), p.1674-1679

2016

Link zum Volltext

Verfügbarkeit prüfen

Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy

Circulation (New York, N.Y.), 2021-02, Vol.143 (8), p.770-779

2021

Link zum Volltext

Verfügbarkeit prüfen

Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR‐RA) Study

Arthritis & rheumatology (Hoboken, N.J.), 2022-10, Vol.74 (10), p.1648-1659

2022

Link zum Volltext

Verfügbarkeit prüfen

Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study

BMJ (Online), 2020-08, Vol.370, p.m2812

2020

Link zum Volltext

Verfügbarkeit prüfen

Use of Osteoporosis Medications after Hospitalization for Hip Fracture: A Cross-national Study

The American journal of medicine, 2015-05, Vol.128 (5), p.519-526.e1

2015

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study

Circulation (New York, N.Y.), 2018-09, Vol.138 (11), p.1116-1126

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 684

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(608)
Mit Volltextzugriff
(636)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(475)
Life Sciences & Biomedicine
(356)
Humans
(230)
Female
(125)
Male
(113)
Physical Sciences
(104)
Rheumatology
(92)
Technology
(76)
Middle Aged
(74)
Chemistry
(70)
Aged
(69)
Patients
(63)
Adult
(62)
Cohort Studies
(59)
Risk Factors
(56)
Rheumatoid Arthritis
(46)
Diabetes
(42)
Pharmacology & Pharmacy
(42)
Science & Technology - Other Topics
(39)
United States - Epidemiology
(39)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Active-comparator design and new-user design in observational studies

Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study

A MaxEnt learner for super-additive counting cumulativity

Bisphosphonates and risk of cardiovascular events: a meta-analysis

Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study

Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease

Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study

Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study

Shift From Adalimumab Originator to Biosimilars in Denmark

Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta‐analysis

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study

Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout

An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout

When Randomized Clinical Trials and Real‐World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis

Calibrating Real‐World Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Crohn’s Disease

Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis

Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims

Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy

Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR‐RA) Study

Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study

Use of Osteoporosis Medications after Hospitalization for Hip Fracture: A Cross-national Study

Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study

Suchergebnisse filtern